Hotline:
+ 49 (0) 2204 2918806
Manufacturer: GlobalData

Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016

SKU:GDHC110PRT / 108610
Language version:English
Report Type:Marktstudie
Nr of pages:45 Pages
Edition:0
Rating:Für diese Studie liegt keine Bewertung vor.
$2,000.00   *
* Click here to switch the currency you want to pay in.
Screenshots
Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016
More about this report
Table of Contents
Other relevant reports
Our guarantee
 

Numbers and facts for this report

The report provides information on the key driver and challenges of the global CKD market. Its scope includes:
Annualized global chronic kidney disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2016. Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Analysis of

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to: • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by ident

Content of the report

Introduction

GlobalData, the industry analysis specialist’s new report, “Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on the global chronic kidney disease market. The report identifies the key trends shaping and driving the global chronic kidney disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global chronic kidney disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key driver and challenges of the global CKD market. Its scope includes:
- Annualized global chronic kidney disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global chronic kidney disease market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with chronic kidney disease.

Highlights

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global chronic kidney disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global chronic kidney disease market landscape? – Identify, understand and capitalize.

Report Highlights
Novartis AG
Reata Pharmaceuticals, Inc
Mitsubishi Tanabe Pharma Corporation
Cytochroma Inc
Keryx Biopharmaceuticals
Astellas Pharma Inc.
FibroGen